Serum PSA, Gleason Score and Clinical Staging in Predicting Biochemical (PSA) Failure After Radical Prostatectomy for Carcinoma of Prostate
|
|
- Roberta White
- 6 years ago
- Views:
Transcription
1 Article ID: WMC ISSN Serum PSA, Gleason Score and Clinical Staging in Predicting Biochemical (PSA) Failure After Radical Prostatectomy for Carcinoma of Prostate Corresponding Author: Mr. Anthony Kodzo - Grey Venyo, Urologist, Urology Department. North Manchester General Hospital - United Kingdom Submitting Author: Mr. Anthony Kodzo - Grey Venyo, Urologist, Urology Department. North Manchester General Hospital - United Kingdom Article ID: WMC Article Type: Audit Submitted on:10-apr-2012, 03:21:05 AM GMT Article URL: Subject Categories:UROLOGY Published on: 10-Apr-2012, 05:42:19 PM GMT Keywords:Adenocarcinoma, Prostate, Radical Prostatectomy, PSA, Gleason score, Stage, Biochemical Failure How to cite the article:venyo A, Imran S, Shah S, Gordon R, Barnes D. Serum PSA, Gleason Score and Clinical Staging in Predicting Biochemical (PSA) Failure After Radical Prostatectomy for Carcinoma of Prostate. WebmedCentral UROLOGY 2012;3(4):WMC Copyright: This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Source(s) of Funding: 0 Competing Interests: None Additional Files: Serum PSA, Gleason Score and Clinical Staging in p WebmedCentral > Audit Page 1 of 26
2 Serum PSA, Gleason Score and Clinical Staging in Predicting Biochemical (PSA) Failure After Radical Prostatectomy for Carcinoma of Prostate Author(s): Venyo A, Imran S, Shah S, Gordon R, Barnes D Abstract Introduction Background: It has been suggested that pre-operative serum PSA, Gleason Score of the tumour as well as stage of the tumour may predict the possibility of PSA (Biochemical) recurrence after radical prostatectomy for localized prostate cancer. Aims: To investigate and to confirm the relationship between biochemical failure rates with regard to: serum PSA levels; Gleason score of prostate biopsy and radical prostatectomy specimens; and Stage. Patients and Methods: Records of the first 50 patients who had undergone radical prostatectomy for localised prostate cancer between December 1999 and January 2006 were reviewed to ascertain the PSA failure rates of the aforementioned groups. Analysis of outcome was done using sure start to determine if the differences in outcome were significant. Results: Total 11 out of 50 patients (22%) had PSA failure. PSA: 11%, 40%, and 60% of patients in the ug/l, and >20ug/L groups respectively developed PSA failure. Gleason score of prostate biopsy specimens: 21.9%, 13.3%, and 100% of patients with tumours scored as Gleason?6, 7, 8-10 respectively had PSA failure. Gleason score of radical prostatectomy specimens: 17%, 20%, and 50% of patients with tumours scored as Gleason?6, 7, 8-10 respectively had PSA failure. Stage of tumour: 4%, 0%, and 43% of patients whose tumours were staged T1-2a, T2b,and T2c-T3 had PSA failure. Statistical analysis has shown that the differences in the outcome of the PSA, stage, and Gleason score of the using the radical prostatectomy specimens was significant. Conclusions: PSA failure rate is higher with higher: serum PSA; Gleason score; and stage. However, individually serum PSA, Gleason score and stage of tumour cannot be used to clearly predict PSA failure. Radical prostatectomy is one of the treatment modalities available for localized prostate cancer with curative intent. Radical prostatectomy which has been available for many years now, is the widely accepted gold standard treatment modality for localized adenocarcinoma of prostate. Radical prostatectomy is usually carried out in specialised Urology Centres. Prior to 1999 Radical Prostatectomy had not been carried out in North Manchester General Hospital in the United Kingdom (The first Radical Prostatectomy was performed in North Manchester General Hospital in 1999). Despite the aim of curative intent of radical prostatectomy some patients subsequently develop biochemical failure post radical prostatectomy and would require further additional alternative treatment. It is generally accepted that individually pre-operative serum Prostate Specific Antigen (PSA) levels, the Gleason score, and clinical stage of the tumour are predictors of PSA / Biochemical recurrence in that patients with localized prostate cancer who have high serum PSA, high Gleason score or higher stage of tumour would be the patients who are likely to develop biochemical failure pursuant to their operations. Patients Materials and Methods Patient population The study population comprised of the initial 50 consecutive men who underwent radical retro-pubic prostatectomy and bilateral pelvic lymph node dissection at North Manchester General Hospital in United Kingdom between 1999 and Serum PSA levels of all the patients were quantitated using the Abbot Architech assay technique before their pre-operative trans-rectal ultrasound scan biopsies and post operatively after one month, 3rd month and at 6 monthly intervals just before or at each out patients clinic follow-up attendance. In cases of possible post operative serum PSA elevations the serum PSA levels were determined at more frequent WebmedCentral > Audit Page 2 of 26
3 intervals. Pre-treatment staging A clinical stage was originally assigned pre-operatively in accordance with the 1992 version of unified tumour node metastasis (TNM) system [1]. All patients underwent digital rectal assessment of their prostates in the out-patient clinic and in the day-service unit at the beginning of their trans-rectal ultrasound scan and biopsies of their prostate glands. Details of the trans-rectal ultrasound of prostate findings were carefully recorded; details of the histology reports as well as details of the patients CT scan/magnetic Resonance Imaging (MRI) scans were also recorded and taken into consideration in the staging of the tumours. Pathological examination All hematoxylin and eosin (H&E) pathological slides of radical prostatectomy specimens were examined by a consultant pathologist with an interest in Urology. The tumour grading was determined based upon the Gleason grading system. The extent of the tumour was determined according to the recommendations of the Royal College of pathologists of the United Kingdom. The capsule of the prostate on each side was carefully examined microscopically for evidence of penetration of cancer through the surface of the prostatic capsule (extra-capsular extension). The seminal vesicles were examined for evidence of tumour involvement; the nodes were examined to confirm or negate nodal involvement of tumour. The status of the surgical margin was also assessed for presence or absence of tumour. Follow-up After the radical prostatectomy, all the patients were reviewed initially in the out-patients clinic within two to four weeks by which time the histology reports of the radical prostatectomy specimens have been received and discussed at the Urology Multi-Disciplinary Team meeting. At the first post-operative review the histology report was discussed with the patients including further follow-up and management plan that was recommended by the Multi-Disciplinary Team. All patients had their serum PSA checked. The patients were then reviewed at 3 months and then at 6 monthly intervals after that. At each review the patients clinical histories were taken to ascertain whether or not they had any complications including voiding symptoms; erectile dysfunction; incontinence and back ache. The serum PSAs were also checked at each visit. The plan for all patients was in case any patient had a serum PSA greater that 20 ug/l then isotope bone scan was done. However, no patient had PSA level higher than 20 ug/l. Post operative serum PSA values were considered elevated (PSA failure / biochemical failure) if values of 0.2 ug/l or greater were obtained on two consecutive visits 1 month apart. In the case when the serum PSA never became undetectable post-operatively, then biochemical failure was considered to have occurred at time zero. Data Collection The 4th author was the only surgeon who performed all the retro-pubic radical prostatectomy operations. The first author assisted in less than 10 of the operations. The audit study was designed by the first and 3rd authors. The first author explained the Gleason grading system and staging of adenocarcinoma of prostate to the 2nd and third authors who then entered the following data into the audit proforma: patient identity details; presenting symptoms; clinical findings including digital rectal examination findings on first consultation and subsequent follow-ups; the serum PSA results at first consultation and at each follow-up; the trans-rectal ultrasound scan findings and histology results of the prostate biopsies; results of CT/MRI scans done in the pre-operative assessment; records of the intra-operative findings; the histology reports of the radical prostatectomy specimens; the post-operative clinical findings including all serum PSA results at each follow-up and any further investigations and further management; the Gleason score and clinical staging of the trans-rectal prostate biopsy specimens; the Gleason score and clinical staging after taking into consideration the histology report and clinical findings of the prostatectomy specimens and findings. All the recorded data entered by the 2nd and 3rd authors were cross checked in the presence of both the second and 3rd authors after checking the patients case records, serum PSA results and dates as entered in the computerized data, the radiological reports entered in the computerized PACS system, clinical findings entered in the clinical notes and in all letters stored in the computerized ALS system. The Gleason score and clinical stage were accepted by all three authors to be correct as well as outcome of patients with regard to PSA (biochemical failure or non-failure and further management. The duration of follow up of each patient was recorded. All the collected data were submitted to the clinical audit department where analyses of data were done without the knowledge of any of the four authors. Analysis of results: The audit department analyzed the results with regard to outcome in relation to percentage of patients without PSA (biochemical) non failure and PSA failure and further management in: 3 different pre-operative serum PSA groups (PSA< 10 ug/l; PSA >10 20 ug/l; WebmedCentral > Audit Page 3 of 26
4 3 Gleason score groups of the pre-operative biopsy specimens (Gleason?6, Gleason 7, Gleason 8-10); Gleason score groups of the radical prostatectomy specimens (Gleason?6, Gleason 7, Gleason 8-10); Clinical staging groups of the radical prostatectomy specimens (stages T1 T2a, T2b, T2c-T3); Form of treatment and follow-up time and outcome of all PSA failures were summarized Results 50 patients underwent Radical prostatectomy for localized prostate cancer. They had a follow-up ranging from 4 months to 7 years with a mean follow-up of 28.7 months. The average age range of the patients was 62 years; 1 patient was aged >70 years; 14 patients were aged between 66 and 70 years; 15 patients were aged between 61 and 65 years;13 were aged between 56 and 60 years; 6 were aged between 50 and 55 years; 1 was less than 50 years old. During the period of follow-up 11 patients (22%) developed PSA failure and one of these patients died of his prostate cancer but the remaining 10 patients were free of clinical disease and they were either referred for adjuvant therapy or have been receiving adjuvant therapy. The only patient who died of his prostate cancer was initially treated with radical radiotherapy prior to his radical prostatectomy however, he developed PSA (Biochemical) failure and he then opted to undergo radical prostatectomy. He also continued to be on hormonal treatment but died. With regard to the ten patients who developed PSA failure the outcomes were as follows: One patient developed PSA failure by the 6th post operative period with PSA values of ug/l, [ng/ml], and 1.95 ug/l, [ng/ml. He was referred to the Oncologist and has been treated by radical radiotherapy and he is also receiving hormonal therapy. One patient developed PSA failure at 4 months with serum PSA level recorded as: 0.22 ug / L. He was referred to the oncologist and he had undergone radical radiotherapy and is receiving hormonal treatment as well. His last serum PSA was < at the time of the study. One patient developed PSA failure at 33 months and has received radical radiotherapy as well as he is on hormonal treatment. His last 3 serum PSAs were One patient developed PSA failure at 4 months post operatively and was referred to the oncologist following which he received radical radiotherapy. His last serum PSA was >0.050 ug/l. One patient developed PSA failure 7 years post operatively and had just been referred to the oncologist. One patient developed PSA failure 4 years post operatively and had just been referred to the oncologist. One patient developed PSA failure 3 years post operatively and was referred to the oncologist following which he received radical radiotherapy. His last 3 serum PSA levels have been: One patient developed PSA failure 8 months post operatively; he was referred to the oncologist and he received radical radiotherapy; his last 2 serum PSA levels were One patient developed PSA failure 2 months post operatively; he was referred to the oncologist and he received radical radiotherapy and is also on hormonal treatment. His last 3 serum PSA levels were One patient developed PSA failure 2 years post operatively; he was referred to the oncologist and he received radical radiotherapy. His last serum PSA was Out of 35 patients with PSAs?6 ug/l, 4 patients (11%) had PSA (biochemical failure) and 35 patients were in the non PSA failure group. Out of 10 patients with pre-operative serum PSAs between 10 and 20 ug/l, 4 had (40%) PSA (biochemical failure and 6 were in the non PSA failure group. Out of 5 patients with pre-operative serum PSAs greater than 20 ug/l 3 (60%) had PSA (biochemical failure) and 4 did not develop PSA (biochemical) failure at follow-up. With regard to outcome and the Gleason score of the pre-operative Trans-rectal ultrasound biopsy of the prostate, out of 32 patients with Gleason score?6, 7 patients (21.9%) had PSA (biochemical) failure and 25 patients did not develop any PSA (biochemical failure);out of 15 patients with Gleason score of 7, 2 patients (13.3%) had PSA (biochemical) failure and 13 did not develop PSA (biochemical failure); out of 3 patients whose tumours were scored as Gleason 8 to 10, all the three patients (100%) had PSA (biochemical) failure (2 patients had PSA failure and 1 patient died as a result of his prostate cancer) With regard to outcome and clinical staging of the radical prostatectomy specimens: out of 25 patients whose tumours were staged as T1-T2a, 1 patient (4%) had PSA (biochemical) failure and 24 patients did not develop any PSA (biochemical) failure; out of two patients with stage T2b tumours none developed PSA (biochemical failure); out of 27 patients with tumours assigned to the T1-T2b stage group only one developed PSA (biochemical failure); out of 23 patients whose tumours were staged as within the T2c and T3 group, 10 (43%) developed PSA (biochemical) failure (one of them died of his tumour)and 13 did not develop PSA (biochemical failure) PSA (biochemical) failures occurred in; 6 out of the 50 WebmedCentral > Audit Page 4 of 26
5 patients (12%) in less than one year, 4 (8%) out of the 50 patients between 1 and 5 years; and in one patient (2%) out of the 50 patients after 7 years. Out of the 11 patients who had PSA failure one patient died as a result of his tumour. (This patient had already been treated by radical radiotherapy and he developed PSA failure post radiotherapy he was informed that it was most likely that he might still continue to have biochemical failure after radical prostatectomy but he was of the opinion that the only other treatment of curative intent was radical prostatectomy. He was therefore treated by radical prostatectomy but developed PSA (biochemical) failure at day zero. There was evidence of up staging to stage T3 in his radical prostatectomy specimen). He received hormonal treatment but died. The remaining 10 patients who developed PSA (biochemical) failure did not develop any evidence of metastasis during the follow-up period. Discussion PSA (biochemical) failure pursuant to definitive treatment with curative intent for localized prostate cancer has been documented to precede clinical evidence of tumour recurrence by a number of months to years [2-4]. Association has been reported between PSA (biochemical) failure pursuant to definitive radiotherapy and increased mortality within the first 10 years after treatment [4]. It was also reported that a trend toward worse outcome exists after 8 years in those with PSA (biochemical) failure [4]. Jhaveri and associates [3] concluded in their study that patients with biochemical failure following radical prostatectomy have excellent over-all survival, equivalent to those without a detectable PSA at 10 years. D Amico and associates [5] reported that patients at high risk for biochemical failure after radiation therapy are also at high risk for death from prostate cancer despite competing causes of morbidity. Prostate-specific antigen has been used as surrogate to measure individual success with regard to failure of surgical treatment [2; 6; 7; 8]. Nevertheless, the natural history of the patient with biochemical failure after radical prostatectomy remains poorly defined, and no criteria for implementing treatment for such patients are uniformly accepted [9]. Pound and associates [2] reported that in patients who have had radical surgery the median time to the discovery of distant metastases is 8 years from the time of isolated biochemical failure and the median actuarial time to death is five years there- after. Hence those with biochemical failure after radical surgery may have a reasonably long life expectancy. An elderly man may die from an unrelated cause before he develops symptoms that require treatment. Results of other studies [2, 3] support the findings of Pound and associates [2]; these indicate an excellent overall survival, equivalent to those without detectable or increasing PSA after definitive therapy. It has been stated that this lack of biochemical failure impact on overall survival in the surgical series may partially reflect more favourable tumour characteristics and lead time [3, 4], but the 10-year actuarial overall survival curves for patients with and without biochemical failure were found to be similar even in high-risk patients (T2b or greater, PSA greater than 10 ng/ml or specimen Gleason score 7 or greater) [3]. Kupelian and associates [4] found a trend toward worse prognosis in those with biochemical failure after 8 years in the radiotherapy series [4]. This would indicate that longer follow-up may show biochemical failure becoming of increasing significance in the prediction of overall survival. It has been observed that some patients with biochemical failure have inferior prognosis than others. Pound and associates [2] proposed an algorithm to predict a man s likelihood of developing metastatic disease following biochemical failure that was based upon the specimen Gleason score (? 7 vs? 8), the time of initial biochemical failure (? 2 years vs? 2 years) and PSA doubling time (PSADT,? 10 months vs? 10 months). Egawa and associates [9] observed the existence of a significant correlation between biochemical failure and overall survival in their study. 11 (22%) out of 50 patients in our study developed PSA (biochemical) failure. 11%, 40% and 60% of patients developed PSA (biochemical) failure respectively in the PSA < 10 ug/l; PSA >10-20 ug/l groups. This observation confirms that localized prostate cancers with higher PSA values are likely to have higher incidence of biochemical failure after radical prostatectomy. Furthermore statistical analysis was done using sure stat to determine whether or not the differences in the biochemical failure rates were significant or not; in view of the fact that the number patients was only 50 varoius tests statistical analysrs were done including: Nominal Independence; Anova; Linear Trend; Nominal Association; and Ordinal. The results of these tests confirm that differences in outcome are significant. Details of the statistical analyses are as follows: With regard to the Gleason score of the trans-rectal ultrasound scan prostate biopsy specimens in our WebmedCentral > Audit Page 5 of 26
6 study, 21.9%, 13.3% and 100% of patients whose tumours were assigned respectively to Gleason? 6; 7; 8-10 groups developed PSA (biochemical) failure after radical prostatectomy. This observation would indicate that patients whose tumours are assigned to the Gleason 8-10 group have a much higher chance of developing PSA (biochemical) failure than those patients whose tumours have been assigned to Gleason scores less than 8. With regard to the Gleason score of the radical prostatectomy specimens in our study, 17%, 20% and 50% of patients whose tumours were assigned respectively to Gleason?6; 7; 8-10 groups developed PSA (biochemical) failure. The difference observed in relation to the outcome of radical prostatectomy and trans rectal ultrasound scan biopsy specimens would be explained by the down/up grading of tumours in the radical prostatectomy specimens which would be more representative of the patients tumours. Various statistical analyses were done using sure Stat including: Nominal Independence, Anova, Linear Trend, Nominal Association, and Ordinal. Even though the results of outcome of PSA failure were noted to be higher with higher Gleason score the differences were not noted to be statistically significant. The ensuing data of the statistical analyses would explain the results: With regard to the Gleason score of the trans-rectal ultrasound scan prostate biopsy specimens in our study, 21.9%, 13.3% and 100% of patients whose tumours were assigned respectively to Gleason? 6; 7; 8-10 groups developed PSA (biochemical) failure after radical prostatectomy. This observation would indicate that patients whose tumours are assigned to the Gleason 8-10 group have a much higher chance of developing PSA (biochemical) failure than those patients whose tumours have been assigned to Gleason scores less than 8. With regard to the Gleason score of the radical prostatectomy specimens in our study, 17%, 20% and 50% of patients whose tumours were assigned respectively to Gleason?6; 7; 8-10 groups developed PSA (biochemical) failure. The difference observed in relation to the outcome of radical prostatectomy and trans rectal ultrasound scan biopsy specimens would be explained by the down/up grading of tumours in the radical prostatectomy specimens which would be more representative of the patients tumours. Various statistical analyses were done using sure Stat including: Nominal Independence, Anova, Linear Trend, Nominal Association, and Ordinal. Even though the results of outcome of PSA failure were noted to be higher with higher Gleason score the differences were not noted to be statistically significant. The ensuing data of the statistical analyses would explain the results: With regard to clinical staging of the radical prostatectomy specimens and outcome in relation to PSA (biochemical failure) 3.7% of patients whose tumours were assigned to stages T1 to T2b developed PSA (biochemical failure); 4% of patients whose tumours were assigned to stages T1-T2a developed PSA (biochemical) failure; there were only 2 patients whose tumours were assigned to stage T2b and none of them developed PSA (biochemical) failure [this number of two is too small to give any meaningful outcome]; 43% of patients whose tumours were assigned to stages T2c-T3 group developed biochemical failure. These results indicate that patients with tumours assigned to stages T1-T2a and T2b have a less chance of developing (PSA) biochemical failure in comparison with patients whose tumours eventually get assigned to the T2c to T3 group. An important finding of clinical significance is the fact that statistical analyses of the outcome with regard to PSA failure and non failure was done which showed that the differences in outcome were significant whether not the patients were divided into either (a) 3 groups [stages T1-T2a, T2b, T2c-T3] or 2 groups [stages T1-T2b, T2c-T3]. Data of the statistical analyses which confirm the above findings are as follows: The results indicate that individually pre-operative serum PSA, Gleason score and clinical stage of the tumours can be used to predict PSA (biochemical) failure in that higher pre-operative serum PSA levels, higher Gleason score, and higher clinical stages are more likely to be associated with PSA (biochemical) failure in comparison with lower serum PSA, lower Gleason score and lower clinical stage. But the fact that PSA (biochemical) failure was found in each PSA subgroup, Gleason score subgroup and clinical stage subgroup would indicate that the individual parameters of serum PSA, Gleason score and clinical stage may be useful in predicting outcome, perhaps it may be a good idea to combine the individual parameters of serum PSA, Gleason score and clinical stage which should be used to divide the patients into 3 separate risk stratification groups to see if risk group stratification would be a more useful way in predicting outcome after radical prostatectomy. The observation that 10 out of 11 patients, who developed PSA (biochemical) failure without any evidence of recurrent tumour and are alive, would be consistent with what WebmedCentral > Audit Page 6 of 26
7 others have previously observed; that patients with PSA (biochemical) failure would live for a number of years without evidence of metastases. Conclusions The results of our study confirm that pursuant to radical prostatectomy for localized adenocarcinoma of prostate: The likelihood of subsequent development of PSA (Biochemical) failure is higher for patients with high pre-operative serum PSA in comparison with those patients whose serum PSAs are low. However pre-operative PSA alone cannot be used to predict which patients would subsequently develop PSA (Biochemical) failure from those who would not develop PSA (Biochemical) failure. The likelihood of PSA (Biochemical) failure is higher for patients with high Gleason score; however the Gleason score of the radical prostatectomy specimen is more reliable than the Gleason score of the trans rectal ultrasound scan biopsy specimen in view of up or down grading of the tumour that may occur in the radical prostatectomy specimen (The radical prostatectomy specimen is more representative of the tumour characteristics in comparison with biopsy specimens). Higher staged tumours especially tumours that are staged higher than T2b are associated higher incidence of subsequent PSA (Biochemical) failure. Nevertheless, the stage of the tumour alone is not enough to adequately predict which patients would subsequently develop PSA (Biochemical) failure from those who would not develop PSA failure. Twenty two percent of our initial 50 patients who underwent radical prostatectomy for localized prostate cancer subsequently developed PSA (Biochemical) failure. The results of our initial experience would suggest that there is the need to combine various risk factors into risk stratification groups to see if risk group stratification would clearly differentiate patients who would develop PSA failure from those who would not develop PSA failure. Acknowledgement References 1. International Union against cancer, TNM Atlas, 3rd edn., 2nd revision, Springer: New York 1992; pp Pound C R, Partin A W, Eisenberger M A, Chan D W, Pearson J D, Walsh P C. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: /PubMed/ 3. Jhaveri F M, Zippe C D, Klein E A, Kupelian P A. Biochemical failure does not predict overall survival after radical prostatectomy for localized prostate cancer: 10-year results: Urology 1999; 54: /PubMed/ 4. Kupelian P A, Buchsbaum J C, Patel C, Eishaikh M, Reddy C A, Zippa C, Klein E A. Impact of biochemical failure on overall survival after radiation therapy for localized prostate cancer in the PSA era. Int J Radial Oncol Biol Phys 2002; 52: D Amico A V, Cote K, Lofredo M, Renshaw A A, Chen M. Pretreatment predictors of time to cancer specific death after prostate specific antigen failure. J Urol 2003; 169: /Article/PubMed/ 6. Egawa S. Detection of prostate cancer by prostate-specific antigen. Biomed Phamarcother 2001; 55: ; /PubMed/ 7. Egawa S, Matsumoto K, Iwamura M, Uchida T, Kuwao S, Koshiba K. Impact of life expectancy and tumor doubling time on the clinical significance of prostate cancer in Japan. Jpn. J Clin Oncol 1997; 27: ; /PubMed/ 8. Partin A W, Oesterling J E. The clinical usefulness of prostate specific antigen: update 1994 J Urol 1994; 15: Egawa S, Matsui Y, Matsum oto K, Suyama K, Arai Y, Kuwao S, Baba S. Impact of biochemical failure on long-term clinical outcome after radical prostatectomy for prostate cancer in Japan. Prostate Cancer and Prostatic Diseases 2004; 7: The audit department of North Manchester General Hospital Dr Sarah Cotterill, who is Research Fellow of the Research Design Service for the North West; University of Manchester; Salford Royal NHS Foundation Trust. United Kingdom. WebmedCentral > Audit Page 7 of 26
8 Illustrations Illustration 1 Statistical analyses of outcome (PSA failure / non failure) based upon pre-operative Serum PSA Contingency table analysis For Table 1 Observed Expected % of row 88.57% 11.43% % of col 79.49% 36.36% 70% Observed Expected % of row 60% 40% % of col 15.38% 36.36% 20% Observed Expected % of row 40% 60% % of col 5.13% 27.27% 10% Total % of n 78% 22% TOTAL number of cells = 6 WebmedCentral > Audit Page 8 of 26
9 Warning: 3 out of 6 cells have EXPECTATION < 5 NOMINAL INDEPENDENCE Chi-square = DF = 2 P = G-square = DF = 2 P = Fisher-Freeman-Halton exact P = ANOVA Chi-square for equality of mean column scores = DF = 1 P = LINEAR TREND Sample correlation (r) = Chi-square for linear trend (M²) = DF = 1 P = NOMINAL ASSOCIATION Phi = Pearson's contingency = Cramér's V = WebmedCentral > Audit Page 9 of 26
10 ORDINAL Goodman-Kruskal gamma = Approximate test of gamma = 0: SE = P < % CI = to Approximate test of independence: SE = P = % CI = to Kendall tau-b = Approximate test of tau-b = 0: SE = P = % CI = to Approximate test of independence: SE = P = % CI = to WebmedCentral > Audit Page 10 of 26
11 Illustration 2 Statistical analyses of outcome (PSA failure / non failure) based upon Gleason Score of trans rectal ultrasound scan prostate Biopsy Specimen Contingency table analysis for table 2 Observed Expected % of row 78.12% 21.88% % of col 64.1% 63.64% 64% Observed Expected % of row 86.67% 13.33% % of col 33.33% 18.18% 30% Observed Expected % of row 33.33% 66.67% % of col 2.56% 18.18% 6% Total % of n 78% 22% TOTAL number of cells = 6 WebmedCentral > Audit Page 11 of 26
12 Warning: 1 out of 6 cells have EXPECTATION < 1 Warning: 3 out of 6 cells have EXPECTATION < 5 NOMINAL INDEPENDENCE Chi-square = DF = 2 P = G-square = DF = 2 P = Fisher-Freeman-Halton exact P = ANOVA Chi-square for equality of mean column scores = DF = 1 P = LINEAR TREND Sample correlation (r) = Chi-square for linear trend (M²) = DF = 1 P = NOMINAL ASSOCIATION Phi = Pearson's contingency = Cramér's V = WebmedCentral > Audit Page 12 of 26
13 ORDINAL Goodman-Kruskal gamma = Approximate test of gamma = 0: SE = P = % CI = to Approximate test of independence: SE = P = % CI = to Kendall tau-b = Approximate test of tau-b = 0: SE = P = % CI = to Approximate test of independence: SE = P = % CI = to These results may indicate that perhaps Gleason score of the trans-rectal ultrasound scan biopsy specimens may not be accurate predictors of PSA biochemical failure. This may be because the biopsy specimens may not be the true representation of the true and accurate Gleason score of the whole prostate considering the fact that down-grading or up-grading may occur after the whole radical prostatectomy specimen has been examined subsequently. In our opinion the surgeon would need to tell each patient prior to his radical prostatectomy that up-grading or down-grading of the Gleason score may occur after radical prostatectomy. Various statistical analyses of the outcome of PSA failure and non failure were also done with regard to the Gleason score of the radical prostatectomy specimens using sure start; the results show p values that are less than the p values of obtained using the Gleason scores of the trans-rectal prostate biopsy specimens; the detailed results are outlined as follows: WebmedCentral > Audit Page 13 of 26
14 Gleason Score Radical prostatectomy specimens (Whole Prostate Specimens) Contingency table analysis for table 3 Observed Expected % of row 82.61% 17.39% % of col 48.72% 36.36% 46% Observed Expected % of row 80% 20% % of col 51.28% 45.45% 50% Observed Expected % of row 0% 100% % of col 0% 18.18% 4% Total % of n 78% 22% TOTAL number of cells = 6 WebmedCentral > Audit Page 14 of 26
15 Warning: 1 out of 6 cells have EXPECTATION < 1 Warning: 2 out of 6 cells have EXPECTATION < 5 NOMINAL INDEPENDENCE Chi-square = DF = 2 P = G-square = DF = 2 P = Fisher-Freeman-Halton exact P = ANOVA Chi-square for equality of mean column scores = DF = 1 P = LINEAR TREND Sample correlation (r) = Chi-square for linear trend (M²) = DF = 1 P = WebmedCentral > Audit Page 15 of 26
16 NOMINAL ASSOCIATION Phi = Pearson's contingency = Cramér's V = ORDINAL Goodman-Kruskal gamma = Approximate test of gamma = 0: SE = P = % CI = to Approximate test of independence: SE = P = % CI = to Kendall tau-b = Approximate test of tau-b = 0: SE = P = % CI = to Approximate test of independence: SE = P = % CI = to WebmedCentral > Audit Page 16 of 26
17 Illustration 3 Statistical analyses of outcome (PSA failure and no failure) based upon tumour staging in to 3 groups (T1-2a; T2b; T2c-T3) Contingency table analysis for table 4 with the tumours divided into 3 stage groups Observed Expected % of row 96% 4% % of col 61.54% 9.09% 50% Observed Expected % of row 100% 0% % of col 5.13% 0% 4% Observed Expected % of row 56.52% 43.48% % of col 33.33% 90.91% 46% Total % of n 78% 22% TOTAL number of cells = 6 WebmedCentral > Audit Page 17 of 26
18 Warning: 1 out of 6 cells have EXPECTATION < 1 Warning: 2 out of 6 cells have EXPECTATION < 5 NOMINAL INDEPENDENCE Chi-square = DF = 2 P = G-square = DF = 2 P = Fisher-Freeman-Halton exact P = ANOVA Chi-square for equality of mean column scores = DF = 1 P = LINEAR TREND Sample correlation (r) = Chi-square for linear trend (M²) = DF = 1 P = NOMINAL ASSOCIATION Phi = Pearson's contingency = Cramér's V = WebmedCentral > Audit Page 18 of 26
19 ORDINAL Goodman-Kruskal gamma = Approximate test of gamma = 0: SE = P < % CI = to Approximate test of independence: SE = P = % CI = to Kendall tau-b = Approximate test of tau-b = 0: SE = P < % CI = to Approximate test of independence: SE = P = % CI = to Statistical analyses of outcome (PSA failure / non failure) Staging (Stages grouped into 2) (T1-T2b; T2c-T3) Contingency table analysis for table 4 modified with the tumours arranged in to 2 groups Observed Expected % of row 96.3% 3.7% % of col 66.67% 9.09% 54% Observed Expected % of row 56.52% 43.48% % of col 33.33% 90.91% 46% Total % of n 78% 22% TOTAL number of cells = 4 WebmedCentral > Audit Page 19 of 26
20 NOMINAL INDEPENDENCE Chi-square = DF = 1 P = G-square = DF = 1 P = Fisher-Freeman-Halton exact P = ANOVA Chi-square for equality of mean column scores = DF = 1 P = LINEAR TREND Sample correlation (r) = Chi-square for linear trend (M²) = DF = 1 P = NOMINAL ASSOCIATION Phi = Pearson's contingency = Cramér's V = (signed) ORDINAL Goodman-Kruskal gamma = Approximate test of gamma = 0: SE = P < % CI = to Approximate test of independence: SE = P = % CI = to Kendall tau-b = Approximate test of tau-b = 0: SE = P < % CI = to Approximate test of independence: SE = P = % CI = to WebmedCentral > Audit Page 20 of 26
21 Illustration 4 Tables PSA Level PSA < 10 ug/l Table 1: Pre-radical prostatectomy PSA levels as predictor of post prostatectomy Biochemical (PSA) failure and non failure outcome of 50 patients who underwent radical prostatectomy for localized prostate cancer between December 1999 and January 2006 PSA Non failure (number of patients) PSA Failure (number of patients) Totals % PSA % >10-<20 ug/l PSA > % ug/l Totals % Percentage failure WebmedCentral > Audit Page 21 of 26
22 Table 2 Gleason Score/Grade of trans-rectal ultrasound scan (TRUSS) specimen in predicting outcome/biochemical failure rate after radical prostatectomy for carcinoma of prostate between December 1999 and January 2006 Gleason Score/Grade PSA Non failure (Number of patients) PSA failure (Number of patients) Died (Number of patients who died as a result of prostate cancer) Totals Percentage failure % % % WebmedCentral > Audit Page 22 of 26
23 Table 3 Gleason score of radical prostatectomy specimens of prostate cancer and prediction of subsequent PSA (Biochemical) failure Gleason score (radical prostatectomy specimen) PSA Non Failure (number of patients) PSA failure (number of patients) Totals Percentage Failure % % % WebmedCentral > Audit Page 23 of 26
24 Table 4 Staging of radical prostatectomy specimen as predictor of outcome (PSA Failure and non failure rate) Clinical Stage (radical prostatectomy specimen) PSA Non failure (Number of Patients) PSA Failure (Number of Patients) Totals T1 2a % T2b % T2c T % Totals % Percentage PSA Failure WebmedCentral > Audit Page 24 of 26
25 Table 5 Management PSA Failure Patients Treatment PSA Failure Time Outcome- PSA level after treatment Previous radical PSA failure after Died radiotherapy, hormonal treatment radiotherapy and then treated by radical prostatectomy Post-op Radiotherapy+ 6 months 0.681/1.95 hormonal Rx Post-op Radiotherapy 4 months 0.22/<0.050 Post-op Radiotherapy 33 months <0.050/<0.050/<0.050 Post-op Radiotherapy 4 months <0.050 Referred to oncologist 7 years Referred to oncologist awaiting outcome Referred to oncologist 4 years Referred to oncologist awaiting outcome Post-op Radiotherapy 3 years <0.050/<0.050/<0.050 Post-op Radiotherapy 8 months <0.050/<0.050/<0.050 Post-op Radiotherapy 2 months <0.050/< hormonal treatment Post-op Radiotherapy 2 years 0.05 WebmedCentral > Audit Page 25 of 26
26 Disclaimer This article has been downloaded from WebmedCentral. With our unique author driven post publication peer review, contents posted on this web portal do not undergo any prepublication peer or editorial review. It is completely the responsibility of the authors to ensure not only scientific and ethical standards of the manuscript but also its grammatical accuracy. Authors must ensure that they obtain all the necessary permissions before submitting any information that requires obtaining a consent or approval from a third party. Authors should also ensure not to submit any information which they do not have the copyright of or of which they have transferred the copyrights to a third party. Contents on WebmedCentral are purely for biomedical researchers and scientists. They are not meant to cater to the needs of an individual patient. The web portal or any content(s) therein is neither designed to support, nor replace, the relationship that exists between a patient/site visitor and his/her physician. Your use of the WebmedCentral site and its contents is entirely at your own risk. We do not take any responsibility for any harm that you may suffer or inflict on a third person by following the contents of this website. WebmedCentral > Audit Page 26 of 26
Radical Prostatectomy Does Not Increase the Risk of Inguinal Hernia
Article ID: WMC003763 ISSN 2046-1690 Radical Prostatectomy Does Not Increase the Risk of Inguinal Hernia Corresponding Author: Dr. Dan Spernat, Senior Lecturer University of Adelaide Urological Surgeon,
More informationSignet-Ring Cell Change in Benign Prostatic Hyperplasia - A Rare Case Report
Article ID: WMC00688 ISSN 2046-1690 Signet-Ring Cell Change in Benign Prostatic Hyperplasia - A Rare Case Report Author(s):Dr. Pallavi Bhuyan, Dr. Smita Mahapatra, Dr. Sujata Pujari, Dr. Jayasree Rath
More informationWhen PSA fails. Urology Grand Rounds Alexandra Perks. Rising PSA after Radical Prostatectomy
When PSA fails Urology Grand Rounds Alexandra Perks Rising PSA after Radical Prostatectomy Issues Natural History Local vs Metastatic Treatment options 1 10 000 men / year in Canada 4000 RRP 15-year PSA
More informationChapter 2. Understanding My Diagnosis
Chapter 2. Understanding My Diagnosis With contributions from Nancy L. Brown, Ph.D.,Palo Alto Medical Foundation Research Institute; and Patrick Swift, M.D., Alta Bates Comprehensive Cancer Program o Facts
More informationOutcomes of Radical Prostatectomy in Thai Men with Prostate Cancer
Original Article Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer Sunai Leewansangtong, Suchai Soontrapa, Chaiyong Nualyong, Sittiporn Srinualnad, Tawatchai Taweemonkongsap and Teerapon
More informationGUIDELINES ON PROSTATE CANCER
10 G. Aus (chairman), C. Abbou, M. Bolla, A. Heidenreich, H-P. Schmid, H. van Poppel, J. Wolff, F. Zattoni Eur Urol 2001;40:97-101 Introduction Cancer of the prostate is now recognized as one of the principal
More informationSupplemental Information
Supplemental Information Prediction of Prostate Cancer Recurrence using Quantitative Phase Imaging Shamira Sridharan 1, Virgilia Macias 2, Krishnarao Tangella 3, André Kajdacsy-Balla 2 and Gabriel Popescu
More informationPreoperative Gleason score, percent of positive prostate biopsies and PSA in predicting biochemical recurrence after radical prostatectomy
JBUON 2013; 18(4): 954-960 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Gleason score, percent of positive prostate and PSA in predicting biochemical
More informationSignet-Ring Cell Change in Benign Prostatic Hyperplasia - A Rare Case Report
Article ID: WMC00688 ISSN 2046-1690 Signet-Ring Cell Change in Benign Prostatic Hyperplasia - A Rare Case Report Author(s):Dr. Pallavi Bhuyan, Dr. Smita Mahapatra, Dr. Sujata Pujari, Dr. Jayasree Rath
More informationProstate Cancer Local or distant recurrence?
Prostate Cancer Local or distant recurrence? Diagnostic flowchart Vanessa Vilas Boas Urologist VFX Hospital FEBU PSA - only recurrence PSA recurrence: 27-53% of all patients undergoing treatment with curative
More informationProstate Case Scenario 1
Prostate Case Scenario 1 H&P 5/12/16: A 57-year-old Hispanic male presents with frequency of micturition, urinary urgency, and hesitancy associated with a weak stream. Over the past several weeks, he has
More informationPost Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series
Post Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series E. Z. Neulander 1, Z. Wajsman 2 1 Department of Urology, Soroka UMC, Ben Gurion University,
More informationCONTEMPORARY UPDATE OF PROSTATE CANCER STAGING NOMOGRAMS (PARTIN TABLES) FOR THE NEW MILLENNIUM
RAPID COMMUNICATION CME ARTICLE CONTEMPORARY UPDATE OF PROSTATE CANCER STAGING NOMOGRAMS (PARTIN TABLES) FOR THE NEW MILLENNIUM ALAN W. PARTIN, LESLIE A. MANGOLD, DANA M. LAMM, PATRICK C. WALSH, JONATHAN
More informationjournal of medicine The new england Preoperative PSA Velocity and the Risk of Death from Prostate Cancer after Radical Prostatectomy abstract
The new england journal of medicine established in 1812 july 8, 4 vol. 31 no. 2 Preoperative PSA Velocity and the Risk of Death from Prostate Cancer after Radical Prostatectomy Anthony V. D Amico, M.D.,
More informationPET imaging of cancer metabolism is commonly performed with F18
PCRI Insights, August 2012, Vol. 15: No. 3 Carbon-11-Acetate PET/CT Imaging in Prostate Cancer Fabio Almeida, M.D. Medical Director, Arizona Molecular Imaging Center - Phoenix PET imaging of cancer metabolism
More informationA schematic of the rectal probe in contact with the prostate is show in this diagram.
Hello. My name is William Osai. I am a nurse practitioner in the GU Medical Oncology Department at The University of Texas MD Anderson Cancer Center in Houston. Today s presentation is Part 2 of the Overview
More informationInfiltrative Brain Mass Due To Progressive Alzheimer's Disease
Article ID: WMC00505 2046-1690 Infiltrative Brain Mass Due To Progressive Alzheimer's Disease Corresponding Author: Dr. Mark Lyons, Associate Professor, Mayo Clinic Arizona, 85054 - United States of America
More informationAJCC Cancer Staging 8 th Edition. Prostate Chapter 58. Executive Committee, AJCC. Professor and Director, Duke Prostate Center
AJCC Cancer Staging 8 th Edition Prostate Chapter 58 Judd W Moul, MD, FACS Executive Committee, AJCC Professor and Director, Duke Prostate Center Duke University Durham, North Carolina Validating science.
More informationSupracondylar Process Congenitalis Of The Femur
Article ID: WMC00544 ISSN 2046-1690 Supracondylar Process Congenitalis Of The Femur Author(s):Dr. S S Suresh Corresponding Author: Dr. S S Suresh, Head of Department, IBRI Regional Referral Hospital, Department
More informationUnderstanding the risk of recurrence after primary treatment for prostate cancer. Aditya Bagrodia, MD
Understanding the risk of recurrence after primary treatment for prostate cancer Aditya Bagrodia, MD Aditya.bagrodia@utsouthwestern.edu 423-967-5848 Outline and objectives Prostate cancer demographics
More informationNIH Public Access Author Manuscript World J Urol. Author manuscript; available in PMC 2012 February 1.
NIH Public Access Author Manuscript Published in final edited form as: World J Urol. 2011 February ; 29(1): 11 14. doi:10.1007/s00345-010-0625-4. Significance of preoperative PSA velocity in men with low
More informationRisk Factors Predicting Mortality in Spinal Cord Injury in Nigeria
Article ID: WMC00807 ISSN 2046690 Risk Factors Predicting Mortality in Spinal Cord Injury in Nigeria Corresponding Author: Dr. Ahidjo Kawu, Consultant Surgeon, Dept of Orthopaedics, UATH, Gwagwalada Abuja
More informationBest Papers. F. Fusco
Best Papers UROLOGY F. Fusco Best papers - 2015 RP/RT Oncological outcomes RP/RT IN ct3 Utilization trends RP/RT Complications Evolving role of elnd /Salvage LND This cohort reflects the current clinical
More informationPCSANM 2015 Seminar. Basic Knowledge: Test for Prostate Cancer. Jerry Cross. 15 item quiz, no grades given
Basic Knowledge: Test for Prostate Cancer Jerry Cross 15 item quiz, no grades given Basic Knowledge: Test for Prostate Cancer From http://prostatesnatchers.blogspot.com/ January 27, 2015 BY MARK SCHOLZ,
More informationOutcomes Following Negative Prostate Biopsy for Patients with Persistent Disease after Radiotherapy for Prostate Cancer
Clinical Urology Post-radiotherapy Prostate Biopsy for Recurrent Disease International Braz J Urol Vol. 36 (1): 44-48, January - February, 2010 doi: 10.1590/S1677-55382010000100007 Outcomes Following Negative
More informationSince the beginning of the prostate-specific antigen (PSA) era in the. Characteristics of Insignificant Clinical T1c Prostate Tumors
2001 Characteristics of Insignificant Clinical T1c Prostate Tumors A Contemporary Analysis Patrick J. Bastian, M.D. 1 Leslie A. Mangold, B.A., M.S. 1 Jonathan I. Epstein, M.D. 2 Alan W. Partin, M.D., Ph.D.
More informationMr PHIP No. 4 Life after treatment for localised prostate cancer
Mr PHIP No. 4 Life after treatment for localised Mr Phip Mr Phip No. 4 / Key points PSA tests are used to monitor cancer control after treatment for. Your PSA drops more quickly after surgery than radiotherapy.
More informationVariation of Superficial Palmar Arch: A Case Report
Article ID: WMC003387 ISSN 2046-1690 Variation of Superficial Palmar Arch: A Case Report Corresponding Author: Dr. Liju S Mathew, Demonstrator, Anatomy, Gulf Medical University, 4184 - United Arab Emirates
More informationRadical prostatectomy as radical cure of prostate cancer in a high risk group: A single-institution experience
MOLECULAR AND CLINICAL ONCOLOGY 1: 337-342, 2013 Radical prostatectomy as radical cure of prostate cancer in a high risk group: A single-institution experience NOBUKI FURUBAYASHI 1, MOTONOBU NAKAMURA 1,
More informationGUIDELINEs ON PROSTATE CANCER
GUIDELINEs ON PROSTATE CANCER (Text update March 2005: an update is foreseen for publication in 2010. Readers are kindly advised to consult the 2009 full text print of the PCa guidelines for the most recent
More informationNICE BULLETIN Diagnosis & treatment of prostate cancer
Diagnosis & treatment of prostate cancer NICE provided the content for this booklet which is independent of any company or product advertised Diagnosis and treatment of prostate cancer Introduction In
More informationWhen to worry, when to test?
Focus on CME at the University of Calgary Prostate Cancer: When to worry, when to test? Bryan J. Donnelly, MSc, MCh, FRCSI, FRCSC Presented at a Canadian College of Family Practitioner s conference (October
More informationCancer. Description. Section: Surgery Effective Date: October 15, 2016 Subsection: Original Policy Date: September 9, 2011 Subject:
Subject: Saturation Biopsy for Diagnosis, Last Review Status/Date: September 2016 Page: 1 of 9 Saturation Biopsy for Diagnosis, Description Saturation biopsy of the prostate, in which more cores are obtained
More informationEarly outcomes of active surveillance for localized prostate cancer
Original Article ACTIVE SURVEILLANCE FOR LOCALIZED PROSTATE CANCER HARDIE et al. Early outcomes of active surveillance for localized prostate cancer CLAIRE HARDIE, CHRIS PARKER, ANDREW NORMAN*, ROS EELES,
More informationin 32%, T2c in 16% and T3 in 2% of patients.
BJUI Gleason 7 prostate cancer treated with lowdose-rate brachytherapy: lack of impact of primary Gleason pattern on biochemical failure Richard G. Stock, Joshua Berkowitz, Seth R. Blacksburg and Nelson
More informationPrognostic value of the Gleason score in prostate cancer
BJU International (22), 89, 538 542 Prognostic value of the Gleason score in prostate cancer L. EGEVAD, T. GRANFORS*, L. KARLBERG*, A. BERGH and P. STATTIN Department of Pathology and Cytology, Karolinska
More informationRadiation Therapy After Radical Prostatectomy
Articles ISSN 1537-744X; DOI 10.1100/tsw.2004.93 Radiation Therapy After Radical Ali M. Ziada, M.D. and E. David Crawford, M.D. Division of Urology, University of Colorado, Denver, Colorado E-mails: aziada@mednet3.camed.eun.eg
More informationElevated PSA. Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017
Elevated PSA Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017 Issues we will cover today.. The measurement of PSA,
More informationClinical Commissioning Policy: Gemcitabine and capecitabine following surgery for pancreatic cancer (all ages)
Clinical Commissioning Policy: Gemcitabine and capecitabine following surgery for pancreatic cancer (all ages) NHS England Reference: 1711P 1 NHS England INFORMATION READER BOX Directorate Medical Operations
More informationPost Radical Prostatectomy Adjuvant Radiation in Patients with Seminal Vesicle Invasion - A Historical Series
Post Radical Prostatectomy Adjuvant Radiation in Patients with Seminal Vesicle Invasion - A Historical Series E. Z. Neulander 1, K. Rubinov 2, W. Mermershtain 2, Z. Wajsman 3 1 Department of Urology, Soroka
More informationA NEURAL NETWORK PREDICTS PROGRESSION FOR MEN WITH GLEASON SCORE 3 4 VERSUS 4 3 TUMORS AFTER RADICAL PROSTATECTOMY
ADULT UROLOGY CME ARTICLE A NEURAL NETWORK PREDICTS PROGRESSION FOR MEN WITH GLEASON SCORE 3 4 VERSUS 4 3 TUMORS AFTER RADICAL PROSTATECTOMY MISOP HAN, PETER B. SNOW, JONATHAN I. EPSTEIN, THERESA Y. CHAN,
More informationDiagnosis and Classification of Prostate Cancer
Patient Information English 32 Diagnosis and Classification of Prostate Cancer The underlined terms are listed in the glossary. prostate biopsy is the only test that can confirm a prostate cancer diagnosis.
More informationBaseline Characteristics of Patients Attending the Memory Clinic Serving the South Shore of Boston
Article ID: ISSN 2046-1690 Baseline Characteristics of Patients Attending the www.thealzcenter.org Memory Clinic Serving the South Shore of Boston Corresponding Author: Dr. Anil K Nair, Chief of Neurology,
More informationGuidelines for the Management of Prostate Cancer West Midlands Expert Advisory Group for Urological Cancer
Guidelines for the Management of Prostate Cancer West Midlands Expert Advisory Group for Urological Cancer West Midlands Clinical Networks and Clinical Senate Coversheet for Network Expert Advisory Group
More informationProviding Treatment Information for Prostate Cancer Patients
Providing Treatment Information for Prostate Cancer Patients For all patients with localized disease on biopsy For all patients with adverse pathology after prostatectomy See what better looks like Contact
More informationQ&A. Overview. Collecting Cancer Data: Prostate. Collecting Cancer Data: Prostate 5/5/2011. NAACCR Webinar Series 1
Collecting Cancer Data: Prostate NAACCR 2010-2011 Webinar Series May 5, 2011 Q&A Please submit all questions concerning webinar content through the Q&A panel Overview NAACCR 2010-2011 Webinar Series 1
More informationWhen radical prostatectomy is not enough: The evolving role of postoperative
When radical prostatectomy is not enough: The evolving role of postoperative radiation therapy Dr Tom Pickles Clinical Associate Professor, UBC. Chair, Provincial Genito-Urinary Tumour Group BC Cancer
More informationS1.04 PRINCIPAL CLINICIAN G1.01 COMMENTS S2.01 SPECIMEN LABELLED AS G2.01 *SPECIMEN DIMENSIONS (PROSTATE) S2.03 *SEMINAL VESICLES
Prostate Cancer Histopathology Reporting Proforma (Radical Prostatectomy) Includes the International Collaboration on Cancer reporting dataset denoted by * Family name Given name(s) Date of birth Indigenous
More informationIntroduction. Original Article
bs_bs_banner International Journal of Urology (2015) 22, 363 367 doi: 10.1111/iju.12704 Original Article Prostate-specific antigen level, stage or Gleason score: Which is best for predicting outcomes after
More informationMUSCLE - INVASIVE AND METASTATIC BLADDER CANCER
10 MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER Recommendations from the EAU Working Party on Muscle Invasive and Metastatic Bladder Cancer G. Jakse (chairman), F. Algaba, S. Fossa, A. Stenzl, C. Sternberg
More informationBook Review: The Role of Education in the Rational use of Medicines
Article ID: WMC002475 ISSN 2046-1690 Book Review: The Role of Education in the Rational use of Medicines Corresponding Author: Dr. P Ravi Shankar, Professor, Medical Education, Pharmacology, KIST Medical
More informationDumbbell Ganglion Of The Foot: Case Report
Article ID: WMC001079 2046-1690 ISSN Dumbbell Ganglion Of The Foot: Case Report Author(s):Dr. S S Suresh, Dr. Hosam Zaki, Dr. Joyce Jose Corresponding Author: Dr. S S Suresh, Head of Department, Ibri Regional
More informationEvaluation of prognostic factors after radical prostatectomy in pt3b prostate cancer patients in Japanese population
Japanese Journal of Clinical Oncology, 2015, 45(8) 780 784 doi: 10.1093/jjco/hyv077 Advance Access Publication Date: 15 May 2015 Original Article Original Article Evaluation of prognostic factors after
More informationVascular Risk Factors in Left Colon Anastomosis Leakage: A Computed Tomography Guided Study
Article ID: WMC003346 ISSN 2046-1690 Vascular Risk Factors in Left Colon Anastomosis Leakage: A Computed Tomography Guided Study Corresponding Author: Dr. Antonio Manenti, Associate Professor, Department
More informationDefinition Prostate cancer
Prostate cancer 61 Definition Prostate cancer is a malignant neoplasm that arises from the prostate gland and the most common form of cancer in men. localized prostate cancer is curable by surgery or radiation
More informationCorresponding Author: Dr. Simon B Thompson, Associate Professor, Psychology Research Centre, Bournemouth University, BH12 5BB - United Kingdom
Article ID: 2046-1690 Thompson Digital Switch: Helping Stroke Patients to Help Themselves by Promoting Proprioception During Therapy. Brief Report and Podcast as a Teaching Aid for Professionals Corresponding
More informationProstate MRI: Who needs it?
Prostate MRI: Who needs it? Fergus Coakley MD, Professor of Radiology and Urology, Vice Chair for Clinical Services, Chief of Abdominal Imaging, UCSF Abdominal Imaging Magnetic Resonance Science Center
More informationLocalized Prostate Cancer Have we finally got it right? Shingai Mutambirwa Professor & Chair-Division Urology DGMAH & SMU Pretoria SOUTH AFRICA
Localized Prostate Cancer Have we finally got it right? Shingai Mutambirwa Professor & Chair-Division Urology DGMAH & SMU Pretoria SOUTH AFRICA ESMO Cape Town 14 Feb 2018 Disclosures Advisory boards/lecturer/consultant-
More information2015 myresearch Science Internship Program: Applied Medicine. Civic Education Office of Government and Community Relations
2015 myresearch Science Internship Program: Applied Medicine Civic Education Office of Government and Community Relations Harguneet Singh Science Internship Program: Applied Medicine Comparisons of Outcomes
More informationTreatment Failure After Primary and Salvage Therapy for Prostate Cancer
307 Treatment Failure After Primary and Salvage Therapy for Prostate Cancer Likelihood, Patterns of Care, and Outcomes Piyush K. Agarwal, MD 1 Natalia Sadetsky, MD, MPH 2 Badrinath R. Konety, MD, MBA 2
More informationCauses of Raised PSA A very large prostate Gland Infection of urine or Prostate Gland Possibility of prostate Cancer
Causes of Raised PSA A very large prostate Gland Infection of urine or Prostate Gland Possibility of prostate Cancer Gleason score Gleason score 2-4: well differentiated (seldom reported now): Low risk
More information2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY
Measure #104 (NQF 0390): Prostate Cancer: Adjuvant Hormonal Therapy for High Risk or Very High Risk Prostate Cancer National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL
More informationA Case of Incisiform Supernumerary Tooth Along With a Impacted Supplemental Tooth In Anterior Maxillary Region
Article ID: WMC004147 ISSN 2046-1690 A Case of Incisiform Supernumerary Tooth Along With a Impacted Supplemental Tooth In Anterior Maxillary Region Corresponding Author: Dr. Keshav K Gautam, Service Senior
More informationDisease-specific death and metastasis do not occur in patients with Gleason score 6 at radical prostatectomy
Disease-specific death and metastasis do not occur in patients with at radical prostatectomy Charlotte F. Kweldam, Mark F. Wildhagen*, Chris H. Bangma* and Geert J.L.H. van Leenders Departments of Pathology,
More informationProstate Cancer Case Study 1. Medical Student Case-Based Learning
Prostate Cancer Case Study 1 Medical Student Case-Based Learning The Case of Mr. Powers Prostatic Nodule The effervescent Mr. Powers is found by his primary care provider to have a prostatic nodule. You
More informationThe Role Of Varma Therapy In Cakana Vatam
Article ID: WMC002906 ISSN 2046-1690 The Role Of Varma Therapy In Cakana Vatam Corresponding Author: Dr. Shanmugasundaram Natarajan, Consultant Varmam Therapy, Siddha Regional Research Institute - India
More informationLouisa Fleure. Advanced Prostate Cancer Clinical Nurse Specialist. Guys and St Thomas NHS Trust
Louisa Fleure Advanced Prostate Cancer Clinical Nurse Specialist Guys and St Thomas NHS Trust The classification of advanced prostate cancer The incidence of patients presenting with, or developing advanced
More informationComparative Analysis Research of Robotic Assisted Laparoscopic Prostatectomy
Comparative Analysis Research of Robotic Assisted Laparoscopic Prostatectomy By: Jonathan Barlaan; Huy Nguyen Mentor: Julio Powsang, MD Reader: Richard Wilder, MD May 2, 211 Abstract Introduction: The
More informationPROVIDING TREATMENT INFORMATION FOR PROSTATE CANCER PATIENTS
PROVIDING TREATMENT INFORMATION FOR PROSTATE CANCER PATIENTS For patients with localized disease on biopsy* For patients with adverse pathology after prostatectomy Contact the GenomeDx Customer Support
More informationNCDB Special Study: Post-Active Treatment Surveillance in Prostate Cancer Webinar #4: NCRA /2/17 Eileen Tonner, MS
NCDB Special Study: Post-Active Treatment Surveillance in Prostate Cancer Webinar #4: NCRA 2017-040 5/2/17 Eileen Tonner, MS Purpose of the Study For patients who have received curative-intent prostate
More informationBilateral Adrenal Myelolipoma: A Case Report and Review of Literature
Article ID: WMC004085 ISSN 2046-1690 Bilateral Adrenal Myelolipoma: A Case Report and Review of Literature Corresponding Author: Dr. Karthikeyan Selvaraju, Assistant Professor, Kasturba Medical College,
More informationda Vinci Prostatectomy
da Vinci Prostatectomy Justin T. Lee MD Director of Robotic Surgery Urology Associates of North Texas (UANT) USMD Prostate Cancer Center (www.usmdpcc.com) Prostate Cancer Facts Prostate cancer Leading
More informationMore HIV Infection Among Housewvies Than Sex Workers In Malaysia
Article ID: WMC001557 ISSN 2046-1690 More HIV Infection Among Housewvies Than Sex Workers In Malaysia Corresponding Author: Mr. Mohamed Najimudeen, Associate Professor, Obstetrics and Gynaecology, Melaka
More informationThe Viability Of Human Embryos After Transport In A Dry Shipper Between Assisted Conception Laboratories
Article ID: WMC001104 2046-1690 The Viability Of Human Embryos After Transport In A Dry Shipper Between Assisted Conception Laboratories Corresponding Author: Ms. Clare Pinkus, Scientist, Hollywood Fertility
More informationDivision of Urologic Surgery and Duke Prostate Center (DPC), Duke University School of Medicine, Durham, NC
LHRH AGONISTS: CONTEMPORARY ISSUES The Evolving Definition of Advanced Prostate Cancer Judd W. Moul, MD, FACS Division of Urologic Surgery and Duke Prostate Center (DPC), Duke University School of Medicine,
More informationHormone Therapy for Prostate Cancer: Guidelines versus Clinical Practice
european urology supplements 5 (2006) 362 368 available at www.sciencedirect.com journal homepage: www.europeanurology.com Hormone Therapy for Prostate Cancer: Guidelines versus Clinical Practice Antonio
More informationProstatectomy as salvage therapy. Cases. Paul Cathcart - Guy s & St Thomas NHS Trust, London
Prostatectomy as salvage therapy Cases Paul Cathcart - Guy s & St Thomas NHS Trust, London Attributes of brachytherapy appeal to young men who place high utility on genitourinary function At risk of
More information20 Prostate Cancer Dan Ash
20 Prostate Cancer Dan Ash 1 Introduction Prostate cancer is a disease of ageing men for which the aetiology remains unknown. The incidence rises up to 30 to 40% in men over 80. The symptoms of localised
More informationRadical Prostatectomy versus Intensity Modulated Radiation Therapy in the Management of Localized Prostate Cancer
Yale University EliScholar A Digital Platform for Scholarly Publishing at Yale Yale Medicine Thesis Digital Library School of Medicine 10-19-2009 Radical Prostatectomy versus Intensity Modulated Radiation
More informationLouisa Fleure. Advanced Prostate Cancer Clinical Nurse Specialist. Guys and St Thomas NHS Trust
Louisa Fleure Advanced Prostate Cancer Clinical Nurse Specialist Guys and St Thomas NHS Trust The classification of advanced prostate cancer The incidence of patients presenting with, or developing advanced
More informationPrognostic Value of Surgical Margin Status for Biochemical Recurrence Following Radical Prostatectomy
Original Article Japanese Journal of Clinical Oncology Advance Access published January 17, 2008 Jpn J Clin Oncol doi:10.1093/jjco/hym135 Prognostic Value of Surgical Margin Status for Biochemical Recurrence
More informationVALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE
Session 3 Advanced prostate cancer VALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE 1 PSA is a serine protease and the physiological role is believed to be liquefying the seminal fluid PSA
More informationUse of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence
Cancer Biomarkers 17 (2016) 83 88 83 DOI 10.3233/CBM-160620 IOS Press Use of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence Michael
More informationHealth Screening Update: Prostate Cancer Zamip Patel, MD FSACOFP Convention August 1 st, 2015
Health Screening Update: Prostate Cancer Zamip Patel, MD FSACOFP Convention August 1 st, 2015 Outline Epidemiology of prostate cancer Purpose of screening Method of screening Contemporary screening trials
More informationEthics in Prehospital Emergency Medicine: An Ethical Dilemma in Patient Communication
Article ID: WMC004247 ISSN 2046-1690 Ethics in Prehospital Emergency Medicine: An Ethical Dilemma in Patient Communication Corresponding Author: Prof. Halvor Nordby, The University of Oslo, Faculty of
More informationPresentation with lymphadenopathy
Presentation with lymphadenopathy Theo M. de Reijke MD PhD FEBU Department of Urology Academic Medical Center Amsterdam Rationale for RRP in N+ disease Prevention local problems Better survival in limited
More informationProstate cancer ~ diagnosis and impact of pathology on prognosis ESMO 2017
Prostate cancer ~ diagnosis and impact of pathology on prognosis ESMO 2017 Dr Puay Hoon Tan Division of Pathology Singapore General Hospital Prostate cancer (acinar adenocarcinoma) Invasive carcinoma composed
More informationGene expression profiling predicts clinical outcome of prostate cancer. Gennadi V. Glinsky, Anna B. Glinskii, Andrew J. Stephenson, Robert M.
SUPPLEMENTARY DATA Gene expression profiling predicts clinical outcome of prostate cancer Gennadi V. Glinsky, Anna B. Glinskii, Andrew J. Stephenson, Robert M. Hoffman, William L. Gerald Table of Contents
More informationAram Kim 4, Myong Kim 1, Se Un Jeong 2, Cheryn Song 1, Yong Mee Cho 2, Jae Yoon Ro 3 and Hanjong Ahn 1*
Kim et al. BMC Urology (2018) 18:7 DOI 10.1186/s12894-018-0321-z RESEARCH ARTICLE Open Access Level of invasion into fibromuscular band is an independent factor for positive surgical margin and biochemical
More informationProstate cancer staging and datasets: The Nitty-Gritty. What determines our pathological reports? 06/07/2018. Dan Berney Maastricht 2018
Prostate cancer staging and datasets: The Nitty-Gritty What determines our pathological reports? Dan Berney Maastricht 2018 Biopsy reporting. How not to do it. The TNM 8 th edition. Changes good and bad
More informationBipartite Patella: Two Cases Reports
Article ID: WMC003501 ISSN 2046-1690 Bipartite Patella: Two Cases Reports Corresponding Author: Dr. Fadwa Chami, Doctor, Hopital Denfants de Rabat - Morocco Submitting Author: Dr. Fadwa Chami, Doctor,
More informationLow risk. Objectives. Case-based question 1. Evidence-based utilization of imaging in prostate cancer
Evidence-based utilization of imaging in prostate cancer Fergus Coakley MD, Professor of Radiology and Urology, Vice Chair for Clinical Services, Chief of Abdominal Imaging, UCSF Objectives State the modalities,
More informationCorrespondence should be addressed to Taha Numan Yıkılmaz;
Advances in Medicine Volume 2016, Article ID 8639041, 5 pages http://dx.doi.org/10.1155/2016/8639041 Research Article External Validation of the Cancer of the Prostate Risk Assessment Postsurgical Score
More informationAppendix 4 Urology Care Pathways
Appendix 4 Urology Care Pathways Cancer Care Pathways outline the steps and stages in the patient journey from referral through to diagnostics, staging, treatment, follow up, rehabilitation and if applicable
More informationIntroduction. Growths in the prostate can be benign (not cancer) or malignant (cancer).
This information was taken from urologyhealth.org. Feel free to explore their website to learn more. Another trusted website with good information is the national comprehensive cancer network (nccn.org).
More informationProstate Cancer: Is There Standard Treatment? Who has prostate cancer? In this article:
Focus on CME at l Université de Montréal Prostate Cancer: Is There Standard Treatment? Pierre I. Karakiewicz, MD, FRCSC; Paul Perrotte, MD, FRCSC; Fred Saad, MD, FRCSC In this article: 1. Risk factors
More informationBIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY
BIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY AZHAN BIN YUSOFF AZHAN BIN YUSOFF 2013 SCENARIO A 66 year old man underwent Robotic Radical Prostatectomy for a T1c Gleason 4+4, PSA 15 ng/ml prostate
More informationSaturation Biopsy for Diagnosis and Staging and Management of Prostate Cancer
Saturation Biopsy for Diagnosis and Staging and Management of Prostate Cancer Policy Number: 7.01.121 Last Review: 2/2018 Origination: 8/2006 Next Review: 8/2018 Policy Blue Cross and Blue Shield of Kansas
More information